By - Reuters
23 March 2023 01:01 p.m. ​All figures in US dollars. The loss announced by Exscientia PLC in the fourth quarter were lower than the Refinitiv mean estimate of losses. The company reported losses of -38 cents per share, 53 cents higher than the same quarter last year when the company reported EPS of -91 cents. Losses of -32 cents per share were anticipated by the two analysts providing estimates for the quarter. Wall Street expected results to range from -41 cents to -24 cents per share, with a forecasted mean of -32 cents per share. The company reported revenue of $8.20 million, which is lower than the estimated $8.23 million. RECOMMENDATIONS * The consensus recommendation for the company is "Buy". * The average consensus recommendation for the biotechnology & medical research peer group is also "Buy". FORECAST CHANGES * There are no analysts currently providing Refinitiv with estimates. * In the last week there have been no earnings estimate revisions by analysts covering the company. There was no change to the number of estimates. YEAR OVER YEAR * The company reported an increase in revenue to $8.2 million from $5.6 million in the same quarter last year.​ * Previous quarterly performance (using earnings preferred measure) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET, MISSED Sep. 30 2022 -0.32​ -0.32 Met Jun. 30 2022 -0.28 -0.29 Missed Mar. 31 2022 -0.31 -0.41 Missed​ Dec. 31 2021 -0.12 -0.91 Missed This summary was machine generated from Refinitiv data March 23 at 01:01 p.m.